 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Trovagene to Launch Analytical Validation Program for Trans-Renal KRAS Mutation Assay
May 02, 2012
Trovagene to Launch Analytical Validation Program for Trans-Renal KRAS Mutation Assay
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Trovagene Using Bio-Rad Digital PCR System for Trans-Renal Pancreatic Cancer MDx
May 31, 2012 / PCR Insider - Trovagene Bets on Digital PCR as Detection Technology for Urine-Based MDx Testing Platform
May 3, 2012 / PCR Insider - Trovagene, MD Anderson Partner on Transrenal BRAF Mutation Detection
January 3, 2013 / PCR Insider - Trovagene Set to Offer Transrenal KRAS Assay on Bio-Rad dPCR System in January
November 29, 2012 / PCR Insider - Trovagene, MD Anderson Team on KRAS Mutation Research
July 3, 2012 / GenomeWeb Daily News